Summary
Recent studies by Boesch et al. have demonstrated that a nonimmunosuppressive cyclosporin analog, SDZ PSC 833 (an analog of cyclosporin D), is an active multidrug-resistance modifier that is at least 10 times more potent than cyclosporin A. In vitro accumulation and cytotoxicity experiments using daunorubicin (DNR) and vincristine (VCR) under the influence of SDZ PSC 833 and cyclosporin A were performed in wild-type (EHR2) and the corresponding highly DNR-resistant (about 80-fold) Ehrlich ascites tumor cells (EHR2/DNR+). In accumulation experiments, both SDZ PSC 833 and cyclosporin A were found to reverse the multidrug-resistant (MDR) phenotype, but to the same degree at equimolar concentrations. Thus, in EHR2/DNR+ cells, both cyclosporins at 5 μg/ml enhanced DNR and VCR accumulation to sensitive levels, but only a negligible effect on DNR accumulation in the drug-sensitive cells was seen. In the clonogenic assay, the cytotoxicity of the two modulators was equal. The lethal dose for 50% of the cell population (LD50) was approx. 7 μg/ml for both compounds, and no toxicity was observed at concentrations below 2 μg/ml. At nontoxic doses, both cyclosporins effectively increased the cytotoxicity of DNR and VCR in a concentration-dependent manner. The dose-response curves were nearly identical and did not demonstrate differences in modulator potency. These data permit the conclusion that cyclosporin A and SDZ PSC 833 do raise the intracellular accumulation of DNR and VCR to the same levels and that SDZPSC 833 does not potentiate cytotoxicity better than cyclosporin A in EHR2/DNR+ cells. However, since the new compound is nonimmunosuppressive and causes less organ toxicity, clinical studies of its MDR modulating effect seem highly relevant.
References
Bachur NR, Moore AL, Bernstein JG, Liu A (1970) Tissue distribution and disposition of daunomycin (NSC-82 151) in mice: fluorometric and isotopic methods. Cancer Chemother Rep 54: 89–94
Beck WT (1987) The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879
Beck WT (1991) Modulators of P-glycoprotein-associated multidrug resistance: In: Molecular and clinical advances in anticancer drug resistance. Kluwer, Boston, p 151
Boesch D, Gavériaux C, Loor F (1991) Reversal of multidrug resistance in CHO cells by cyclosporin A and other resistance modifying agents. J Cell Pharmacol 2: 92
Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vitro circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226
Bradley G, Juranka PF, Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87
Danø K (1971) Development of resistance to daunomycin (NSC-82 151) in Ehrlich ascites tumor. Cancer Chemother Rep 55: 133
Danø K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466
Foxwell BMJ, Mackie A, Ling V, Ryffel B (1989) Identification of the multi-drug resistance related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36: 543
Friche E, Skovsgaard T, Nissen NI (1987) Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol 19: 35
Friche E, Jensen PB, Sehested M, Demant EJF, Nissen NI (1990) The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 2: 297
Georges E, Sharom FJ, Ling V (1990) Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 21: 185
Jensen PB, Roed H, Vindeløv LL, Christensen IJ, Hansen HH (1989) Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines. Invest New Drugs 7: 307
Osicka R, Seeber S, Pannenbiacker R, Sall D, Glatte P, Schmidt CG (1986) Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol 18: 298
Pastan I, Gottesman MM (1987) Multidrug resistance in human cancer. N Engl J Med 316: 1388
Riordan JR, Ling V (1985) Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 28: 51
Roed H, Christensen IJ, Vindeløv LL, Spang-Thomsen M, Hansen HH (1987) Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer lines. Eur J Cancer Clin Oncol 23: 177
Sehested M, Jensen PB, Skovsgaard T, Bindslev N, Demant EJF, Friche E, Vindeløv L (1989) Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators. Br J Cancer 60: 809
Skovsgaard T (1978) Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res 38: 4722
Slater LM, Sweet P, Stupecky M, Gupta S (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77: 1405
Twentyman PR (1988) A possible role for cyclosporins in cancer chemotherapy. Anticancer Res 8: 985
Twentyman PR, Fox NE, White DJG (1987) Cyclosporin A and its analogues as modifiers of Adriamycin and vincristine resistance in a multi-drug resistance human lung cancer cell line. Br J Cancer 56: 55
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Friche, E., Buhl Jensen, P. & Nissen, N.I. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother. Pharmacol. 30, 235–237 (1992). https://doi.org/10.1007/BF00686321
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686321